sefa ozel By Levi at Elliott Wave Trader, Produced with Avi Gilburt I would imagine that in our time as investors, the majority, if not all, have been caught at least once. It’s that one company that just becomes even more of a bargain. The valuations are apparently so compelling that we may even double down on a losing stance, assured of our position and sleeping under the blanket of a seemingly warm dividend.
Yet, the price continues to flounder and that blanket which used to provide so much comfort simply does not cover what it did before. Might this be the case in Bristol-Myers Squibb ( NYSE: BMY )? Let’s dive into the details. First, we will dive into the fundamentals with Lyn Alden.
Then, it will be a measure of the current structure of price on the chart. Here we go. Lyn Alden Discusses The Current Scenario For BMY: “Bristol-Myers Squibb (BMY) has arguably been the most disappointing stock pick in a while.
In my view, this is the one that's showing the most signs of being a value trap. It was a big outperformer back in 2022: When most things were going down, some of our energy and healthcare names were rising, and BMY was in that pack. But in 2023 and 2024, BMY has been a persistent dud, and not just in terms of price action.
chart by Lyn Alden - FastGraphs My analysis over the past couple of weeks is that the stock price has likely fallen far more than the underlying value of the company. I think a price to free cash flow ratio of under 7x is rather pessimistic,.
